MedTrace Logo

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

NCT05278338 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-07-18

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

JMT103

subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

DRUG

Denosumab

subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

DRUG

Placebo

subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Weibo Xia · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278338 on ClinicalTrials.gov